Robyn P M Saw

List of Publications by Year
in descending order

111 papers	7,216 citations	81900 39 h-index	62596 80 g-index
112 all docs	112 docs citations	112 times ranked	9584 citing authors

#	Article	IF	Citations
1	Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. Journal of Investigative Dermatology, 2022, 142, 1607-1616.	0.7	11
2	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	1.5	21
3	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	16.8	64
4	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.6	3
5	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surgery, 2022, 157, 335.	4.3	20
6	The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 2022, 29, 2871-2881.	1.5	5
7	Melanoma and Quality of Life. , 2022, , 439-466.		2
8	OUP accepted manuscript. Journal of Surgical Case Reports, 2022, 2022, rjac172.	0.4	0
9	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 2022, , .	0.6	1
10	Reflectance confocal microscopy â€“ a nonâ€invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
11	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	2.8	4
12	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Frontiers in Oncology, 2022, 12, 820510.	2.8	2
13	Effect of the <scp>SunSafe</scp> Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. Clinical and Experimental Dermatology, 2022, , .	1.3	0
14	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	30.7	121
15	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. European Journal of Surgical Oncology, 2021, 47, 1145-1151.	1.0	5
16	Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIAâ€“D Melanoma. Annals of Surgical Oncology, 2021, 28, 4561-4569.	1.5	11
17	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
18	Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review. BMJ Open, 2021, 11, e040751.	1.9	13

#	Article	IF	Citations
19	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature Medicine, 2021, 27, 256-263.	30.7	190
20	Treatment of in-transit melanoma metastases using intralesional PV-10. Melanoma Research, 2021, 31, 232-241.	1.2	2
21	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. European Journal of Cancer, 2021, 148, 51-57.	2.8	16
22	Reply to: CT and PET/CT Surveillance in Stage IIIA-D Melanoma Results in More False-Positive Than True-Positive Findings and Should Not be Routinely Recommended, by Nicholas Taylor et al.. Annals of Surgical Oncology, 2021, 28, 819-820.	1.5	4
23	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/â^' Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 2021, 13, 3186.	3.7	11
24	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	1.2	22
25	Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology, 2021, 34, 1999-2008.	5.5	16
26	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 2021, 91, 3-13.	0.7	7
27	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	2.8	1
28	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 2021, 28, 6109-6123.	1.5	8
29	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. OncoImmunology, 2020, 9, 1659093.	4.6	62
30	Development of the Melanoma Concerns Questionnaire (MCQâ€28); refinement of the EORTC QLQâ€MEL38 module. Psycho-Oncology, 2020, 29, 321-330.	2.3	7
31	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 2020, 11, 5259.	12.8	102
32	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 2020, 31, 1569-1579.	1.2	18
33	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. BMJ Open, 2020, 10, e037857.	1.9	4
34	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer, 2020, 126, 4717-4725.	4.1	14
35	Multiplex melanoma families are enriched for polygenic risk. Human Molecular Genetics, 2020, 29, 2976-2985.	2.9	9
36	Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. Melanoma Research, 2020, 30, 358-363.	1.2	14

#	Article	IF	Citations
37	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Cancers, 2020, 12, 2228.	3.7	22
38	Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e.	1.4	0
39	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	3.4	13
40	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. Journal of Clinical Oncology, 2020, 38, 2719-2727.	1.6	84
41	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
42	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	12.8	165
43	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
44	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
45	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 948-960.	10.7	346
46	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€“C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	10.7	126
47	Molecular Genomic Profiling of MelanocyticÂNevi. Journal of Investigative Dermatology, 2019, 139, 1762-1768.	0.7	55
48	False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 2019, 26, 1860-1868.	1.5	29
49	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	16.8	547
50	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naÃ¯ve Melanoma Patients: Implications for Clinical Trials. Clinical Cancer Research, 2019, 25, 3247-3258.	7.0	27
51	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers, 2019, 11, 1905.	3.7	14
52	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. International Journal of Cancer, 2019, 144, 1049-1060.	5.1	54
53	Interâ€•and intrapatient heterogeneity of indoleamine 2,3â€dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. Histopathology, 2019, 74, 817-828.	2.9	16
54	Subungual Melanoma of the Hand. Annals of Surgical Oncology, 2019, 26, 1035-1043.	1.5	28

#	Article	IF	Citations
55	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. Annals of Surgical Oncology, 2019, 26, 25-32.	1.5	21
56	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. OncoImmunology, 2019, 8, e1537581.	4.6	61
57	Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.. Journal of Clinical Oncology, 2019, 37, 9511-9511.	1.6	3
58	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 2019, 10, 930-941.	1.8	31
59	Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma. JAMA Dermatology, 2018, 154, 420.	4.1	29
60	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-NaÃ¯ve Melanoma Patients and Expand Significantly During Antiâ€“PD-1 Treatment. Clinical Cancer Research, 2018, 24, 3036-3045.	7.0	297
61	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of Surgical Oncology, 2018, 25, 2541-2549.	1.5	35
62	Discrimination, Bullying and Harassment in Surgery: A Systematic Review and Metaâ€analysis. World Journal of Surgery, 2018, 42, 3867-3873.	1.6	30
63	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	1.2	135
64	Metastatic Melanoma to the Colon, Rectum, and Anus: A 50-Year Experience. Annals of Surgical Oncology, 2018, 25, 2178-2183.	1.5	14
65	Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).. Journal of Clinical Oncology, 2018, 36, TPS9604-TPS9604.	1.6	8
66	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.. Journal of Clinical Oncology, 2018, 36, 9518-9518.	1.6	0
67	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192
68	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
69	Melanoma patient imaging in the era of effective systemic therapies. European Journal of Surgical Oncology, 2017, 43, 1517-1527.	1.0	14
70	5â€Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. Journal of Cutaneous Pathology, 2017, 44, 249-255.	1.3	14
71	Incidental detection of colorectal lesions by FDG PET/CT scans in melanoma patients. European Journal of Surgical Oncology, 2017, 43, 2163-2169.	1.0	3
72	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clinical Cancer Research, 2017, 23, 6054-6061.	7.0	75

#	Article	IF	Citations
73	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Modern Pathology, 2017, 30, 1538-1550.	5.5	33
74	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 2017, 30, 1666-1676.	5.5	150
75	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. Journal of Clinical Oncology, 2017, 35, 1721-1729.	1.6	40
76	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. American Journal of Surgical Pathology, 2016, 40, 786-795.	3.7	41
77	The molecular profile of metastatic melanoma in Australia. Pathology, 2016, 48, 188-193.	0.6	26
78	Workplace Bullying in Surgery. World Journal of Surgery, 2016, 40, 2560-2566.	1.6	69
79	BRAF^{V600E} and NRAS^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 2016, 69, 680-686.	2.9	28
80	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1â€“2Âmm in Thickness): Analysis of 2131 Patients Treated at a Single Center. Annals of Surgical Oncology, 2016, 23, 1071-1081.	1.5	31
81	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Caseâ€“Control Study. Annals of Surgical Oncology, 2016, 23, 1082-1089.	1.5	43
82	Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. European Journal of Surgical Oncology, 2015, 41, 830-836.	1.0	19
83	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Annals of Surgical Oncology, 2015, 22, 475-481.	1.5	131
84	Cross-cultural development of a quality-of-life measure for patients with melanoma. Melanoma Research, 2015, 25, 47-58.	1.2	16
85	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	7.1	146
86	Diverse presentations of acral melanoma. Australian Family Physician, 2015, 44, 43-5.	0.5	0
87	A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. Melanoma Research, 2014, 24, 252-260.	1.2	35
88	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. Clinical Cancer Research, 2014, 20, 1965-1977.	7.0	447
89	Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. Annals of Surgical Oncology, 2014, 21, 3108-3116.	1.5	33
90	Primary Melanoma Location on the Scalp is an Important Risk Factor for Brain Metastasis: A Study of 1,687 Patients with Cutaneous Head and Neck Melanomas. Annals of Surgical Oncology, 2014, 21, 3985-3991.	1.5	35

#	Article	IF	Citations
91	The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (2â€“4 mm in Thickness). Annals of Surgery, 2014, 260, 1095-1102.	4.2	12
92	The FACT-Melanoma Quality-of-Life Instrument. Melanoma Research, 2013, 23, 61-69.	1.2	12
93	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 2013, 12, 1332-1342.	4.1	71
94	The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. Annals of Surgery, 2013, 258, 152-157.	4.2	56
95	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery, 2012, 255, 128-133.	4.2	103
96	The Management of Cervical Lymph Nodes in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 3926-3932.	1.5	17
97	Evaluation of Incomplete Sentinel Node Biopsy Procedures and Sentinel Node Positivity Rates as Surgical Quality-Assurance Parameters in Melanoma Patients. Annals of Surgical Oncology, 2012, 19, 3919-3925.	1.5	6
98	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 1782-1789.	1.5	30
99	Dramatic regression of cutaneous, nodal, and visceral melanoma metastases. Journal of the American Academy of Dermatology, 2011, 65, 665-666.	1.2	7
100	Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. Annals of Surgery, 2009, 249, 473-480.	4.2	61
101	Keystone Flap Reconstruction of Primary Melanoma Excision Defects of the Legâ€”The End of the Skin Graft?. Annals of Surgical Oncology, 2008, 15, 2867-2873.	1.5	85
102	Guidelines for imaging in cutaneous melanoma. Nuclear Medicine Communications, 2008, 29, 877-879.	1.1	7
103	Imaging in cutaneous melanoma. Nuclear Medicine Communications, 2008, 29, 847-876.	1.1	60
104	Defining Lower Limb Lymphedema After Inguinal or Ilio-Inguinal Dissection in Patients With Melanoma Using Classification and Regression Tree Analysis. Annals of Surgery, 2008, 248, 286-293.	4.2	59
105	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. American Journal of Clinical Pathology, 2007, 127, 385-397.	0.7	72
106	A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 597-608.	1.5	67
107	Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy. Annals of Surgical Oncology, 2005, 12, 429-439.	1.5	109
108	p53, Deleted in Colorectal Cancer Gene, and Thymidylate Synthase as Predictors of Histopathologic Response and Survival in Low, Locally Advanced Rectal Cancer Treated With Preoperative Adjuvant Therapy. Diseases of the Colon and Rectum, 2003, 46, 192-202.	1.3	72

#	Article	IF	Citations
109	p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. British Journal of Surgery, 2002, 89, 1409-1415.	0.3	32
110	Rectal Cancer: Changing Patterns Of Referral For Radiation Therapy 1982-1997. Australian and New Zealand Journal of Surgery, 2000, 70, 553-559.	0.2	5
111	Cutaneous sarcoidosis due to immuneâ€checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor. Skin Health and Disease, 0, , e71.	1.5	2